Intelligence / Healthtech / New Clinical Trials / Brainfarma Industria Química e Farmacêutica S/A
Clinicaltrial registered5 Nov 2026
Brainfarma Industria Química e Farmacêutica S/A
5 Nov 2026: Trial registered · Cosmetic Efficacy Evaluation of Hydraporin AI Cream in Individuals With Atopic Dermatitis and Psoriasis. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 5 Nov 2026
- Title
- Cosmetic Efficacy Evaluation of Hydraporin AI Cream in Individuals With Atopic Dermatitis and Psoriasis
- Conditions
- Atopic Dermatitis, Psoriasis
- Phase
- Not applicable
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- Brazil
- Country
- Brazil
- Reference
- NCT07918560
- Location
- Brazil
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Brainfarma Industria Química e Farmacêutica S/A
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from Brazil
New Clinical Trials
17 NovAstraZenecatrial registered · A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLCClinical16 NovDr. August Wolff GmbH & Co. KG Arzneimitteltrial registered · Non-inferiority Study of a Hydroxyapatite and Calcium Hypophosphite Toothpaste Compared With Two Comparator Toothpastes in Dentin HypersensitivityClinical12 NovNovo Nordisk A/Strial registered · A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothClinical12 NovNovo Nordisk A/Strial registered · AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothClinical12 NovNovo Nordisk A/Strial registered · A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or BothClinical5 NovNovo Nordisk A/Strial registered · A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and ObesityClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.